Teachers Retirement System of The State of Kentucky Has $751,000 Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Teachers Retirement System of The State of Kentucky reduced its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 8.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,814 shares of the medical research company’s stock after selling 363 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in Charles River Laboratories International were worth $751,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of CRL. Toronto Dominion Bank raised its holdings in Charles River Laboratories International by 1.6% during the third quarter. Toronto Dominion Bank now owns 25,617 shares of the medical research company’s stock worth $5,046,000 after buying an additional 397 shares during the last quarter. Neo Ivy Capital Management bought a new stake in shares of Charles River Laboratories International during the third quarter worth about $966,000. Gould Capital LLC acquired a new stake in shares of Charles River Laboratories International in the 3rd quarter worth about $1,225,000. M&T Bank Corp lifted its position in Charles River Laboratories International by 3.4% in the 3rd quarter. M&T Bank Corp now owns 2,001 shares of the medical research company’s stock valued at $394,000 after acquiring an additional 66 shares in the last quarter. Finally, Nomura Asset Management Co. Ltd. boosted its stake in Charles River Laboratories International by 13.7% during the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 15,592 shares of the medical research company’s stock valued at $3,071,000 after purchasing an additional 1,882 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Insider Buying and Selling

In other news, Director Richard F. Wallman sold 6,621 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the transaction, the director now directly owns 12,386 shares in the company, valued at approximately $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Trading Down 3.3 %

Shares of CRL stock opened at $183.16 on Thursday. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. The firm has a market cap of $9.37 billion, a P/E ratio of 22.92, a PEG ratio of 5.00 and a beta of 1.38. The company has a 50 day moving average of $194.33 and a 200-day moving average of $202.55. Charles River Laboratories International, Inc. has a 12-month low of $176.48 and a 12-month high of $275.00.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.43 by $0.16. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company’s revenue was down 1.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.72 earnings per share. Sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently commented on CRL shares. Bank of America lowered their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. UBS Group raised their price objective on Charles River Laboratories International from $240.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Evercore ISI lifted their price objective on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a report on Thursday, November 7th. Citigroup downgraded shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and lowered their target price for the company from $215.00 to $175.00 in a report on Tuesday, October 1st. Finally, TD Cowen boosted their price target on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a report on Monday, November 11th. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $214.00.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).